
The results also indicate that these patients also had a 55% lower risk of a major cardiac event if they had sustained a recent heart attack. The patients were also less likely to expire from cardiac-related and other causes, and less likely to have a major cardiac event with a more potent vaccine when compared to the standard seasonal vaccine.
While the study results are promising, study leader Jacob Udell, MD, cardiologist, Women’s College Hospital, and clinician-scientist at the University of Toronto, and senior co-author Michael Farkouh, MD, MSc, FACC, chair and director of the Peter Munk Center of Excellence in Multinational Clinical Trials, note that a large prospective clinical trial is needed in order to confirm the effectiveness and safety of the vaccine as a therapy to reduce the risk of stroke or heart attack in heart disease patients.
Farkouh adds that the researchers aim to, “build on this research with a definitive, international trial to conclusively determine whether the flu shot prevents heart attacks.”
A news release from UHN also emphasizes that if the prevention method is proven safe, it could hold significant implications for patients at risk of stroke and heart disease.
Source: UHN